Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Basit Öğe Kaydı
dc.authorscopusid25227432300
dc.authorscopusid10638825900
dc.authorscopusid26424918300
dc.authorscopusid55888626900
dc.authorscopusid7003283666
dc.authorscopusid7003706434
dc.authorscopusid7103125178
dc.contributor.authorAnastasiou, Olympia E.
dc.contributor.authorCaruntu, Florin A.
dc.contributor.authorCurescu, Manuela G.
dc.contributor.authorYalcin, Kendal
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorGürel, Selim
dc.contributor.authorZeuzem, Stefan
dc.date.accessioned2024-08-25T18:46:13Z
dc.date.available2024-08-25T18:46:13Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground & Aims: Until recently, pegylated interferon-alfa-2a (PEG-IFNa) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). Treatment with PEG-IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression in 44% of patients at the end of therapy but did not prevent short-term relapses within 24 weeks. The virological and clinical long-term effects after prolonged PEG-IFNa-based treatment of hepatitis D are unknown.Methods: In the HIDIT-II study patients (including 40% with liver cirrhosis) received 180 mu g PEG-IFNa weekly plus 300 mg TDF once daily (n = 59) or 180 mu g PEG-IFNa weekly plus placebo (n = 61) for 96 weeks. Patients were followed until week 356 (5 years after end of therapy).Results: Until the end of follow-up, 16 (13%) patients developed liver-related complications (PEG-IFNa + TDF, n = 5 vs PEG-IFNa + placebo, n = 11; p = .179). Achieving HDV suppression at week 96 was associated with decreased long-term risk for the development of hepatocellular carcinoma (p = .04) and hepatic decompensation (p = .009). Including complications irrespective of PEG-IFNa retreatment status, the number of patients developing serious complications was similar with (3/18) and without retreatment with PEG-IFNa (16/102, p > .999) but was associated with a higher chance of HDV-RNA suppression (p = .024, odds ratio 3.9 [1.3-12]).Conclusions: Liver-related clinical events were infrequent and occurred less frequently in patients with virological responses to PEG-IFNa treatment. PEG-IFNa treatment should be recommended to HDV-infected patients until alternative therapies become available. Retreatment with PEG-IFNa should be considered for patients with inadequate response to the first course of treatment.en_US
dc.description.sponsorshipOpen Access funding enabled and organized by Projekt DEAL.en_US
dc.description.sponsorshipOpen Access funding enabled and organized by Projekt DEAL.en_US
dc.identifier.doi10.1111/liv.15745
dc.identifier.issn1478-3223
dc.identifier.issn1478-3231
dc.identifier.pmid37787009en_US
dc.identifier.scopus2-s2.0-85173433341en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/liv.15745
dc.identifier.urihttps://hdl.handle.net/11454/101813
dc.identifier.wosWOS:001079543600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofLiver Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectHDVen_US
dc.subjectHIDIT-IIen_US
dc.subjectinterferonen_US
dc.subjectlong-term outcomeen_US
dc.subjectNUCen_US
dc.subjectChronic Delta-Hepatitisen_US
dc.subjectInterferonen_US
dc.subjectAlpha-2aen_US
dc.titleFive-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis Den_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu